Inhibrx to webcast interim Phase 2 HexAgon results for INBRX-106 in HNSCC

Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc.

INBX

0.00
  • Inhibrx scheduled a May 11, 2026 webcast to present interim results from randomized Phase 2 HexAgon study of INBRX-106 combined with pembrolizumab versus pembrolizumab alone in first-line head and neck squamous cell carcinoma.
  • Update will focus on early read on whether adding INBRX-106 improves clinical benefit while maintaining acceptable safety in treatment-naïve, PD-L1 positive patients with metastatic or unresectable recurrent disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibrx Biosciences Inc. published the original content used to generate this news brief on May 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.